Supernus Pharmaceuticals (SUPN) Non-Current Deferred Tax Liability (2015 - 2025)

Supernus Pharmaceuticals (SUPN) has 8 years of Non-Current Deferred Tax Liability data on file, last reported at $981000.0 in Q1 2025.

• Non-Current Deferred Tax Liability for Q1 2025 came in at $981000.0, down 94.97% year-over-year; the trailing twelve-month figure through Mar 2025 was $981000.0 (down 94.97% YoY), and the FY2024 annual result was $5.0 million, down 96.83% from the prior year.
• Non-Current Deferred Tax Liability eased to $981000.0 in Q1 2025 per SUPN's latest filing, from $5.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $229.6 million in Q4 2021 and troughed at $981000.0 in Q1 2025.
• A 5-year average of $52.3 million and a median of $35.2 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2021 and 2024: Non-Current Deferred Tax Liability soared 552.1% in 2021, then sank 96.83% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $229.6 million in 2021, then tumbled by 78.31% to $49.8 million in 2022, then surged by 213.73% to $156.3 million in 2023, then slumped by 96.83% to $5.0 million in 2024, then slumped by 80.23% to $981000.0 in 2025.
• Business Quant data shows SUPN's Non-Current Deferred Tax Liability at $981000.0 in Q1 2025, $5.0 million in Q4 2024, and $7.4 million in Q3 2024.